OncoMatch/Clinical Trials/NCT05528887
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
Is NCT05528887 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Autologous CAR-T cells and Fludarabine for relapsed/refractory hematological malignancies.
Treatment: Autologous CAR-T cells · Fludarabine · Cyclophosphamide — The primary purpose of this study is to determine the safety and efficacy of novel autologous CAR-T cells in patients with relapsed/refractory hematological malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard therapy
refractory to, or relapsing after standard therapy
Lab requirements
Kidney function
Serum creatinine (Cr) ≤ 2 × upper limit of normal (ULN)
Liver function
Serum bilirubin ≤ 35 μmol/L; AST/ALT < 2
Cardiac function
Brain natriuretic peptide (BNP)<80 pg/mL; LVEF < 50% [excluded]; Class III or IV heart failure as defined by NYHA [excluded]
Adequate organ functions: Serum bilirubin ≤ 35 μmol/L; AST/ALT < 2; Serum creatinine (Cr) ≤ 2 × ULN; BNP<80 pg/mL. History of cardiac diseases: LVEF < 50%; Class III or IV heart failure as defined by NYHA
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify